glp 1 and statins Slash GLP-1 (Human Trial) – 44 Second Summary, Human trial data published in a major journal show that statins cause insulin resistance deplete GLP-1 levels in humans. This should have Cardiovascular Protective Properties of GLP-1

As Fillit noted, GLP-1 drugs would be very good candidates to be delivered in combination with an anti-amyloid drug like Eisai and Biogens recently approved Leqembi (lecanemab) or Lillys investigational donanemab, because there is no overlap in the mechanism of action

Lancet (lond Engl)

Notice the smoother, more defined abdominal shape and the overall enhancement in contour achieved through this combined approach

Injection Site Reactions, Tissue Tolerance, and Rotation Protocols Both subcutaneous and intramuscular LIPO-C injections carry risk of localized injection site reactions

In one study, exogenous administration of combined GLP-1R/Y2-R agonists partially mimicked the positive effects of bariatric surgery but did not lead to the anticipated overall metabolic improvements 10 suggesting other pathways are also involved

Jomova K, Alomar SY, Nepovimova E, Kuca K, Valko M